

Tofranil Thymoleptic : major breakthrough in the treatment of depression : Geigy.

Contributors

Geigy Pharmaceuticals

Publication/Creation

[1960?]

Persistent URL

<https://wellcomecollection.org/works/x8jy5ftc>

License and attribution

Conditions of use: it is possible this item is protected by copyright and/or related rights. You are free to use this item in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s).




Wellcome Collection
183 Euston Road
London NW1 2BE UK
T +44 (0)20 7611 8722
E library@wellcomecollection.org
<https://wellcomecollection.org>

Tofranil[®]
Thymoleptic

**Major
breakthrough
in the
treatment of
depression**

Geigy



Tofranil[®] Thymoleptic

Specific therapeutic measure for the endogenous and reactive depressive states

Dosage Treatment should be commenced by administering one 25 mg tablet three times a day for the first week and gradually increasing this during the second week to two 25 mg tablets three times daily. A full therapeutic response is usually achieved within 2-3 weeks of commencing treatment. The dosage may then be reduced in stages to a maintenance level, which may be as low as one 25 mg tablet twice a day.

For the achievement of therapeutic levels Tofranil should be given at regular intervals throughout the day.

Tofranil is available in tablets, each containing 25 mg N-(γ -Dimethylaminopropyl)-iminodibenzyl hydrochloride.



Geigy Pharmaceutical Company Ltd., Wythenshawe, Manchester 23

JULY 1960

PH 162